Marshall Wace LLP Acquires New Stake in ChromaDex Co. (NASDAQ:CDXC)

Marshall Wace LLP acquired a new stake in shares of ChromaDex Co. (NASDAQ:CDXC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,577 shares of the company’s stock, valued at approximately $56,000.

A number of other hedge funds also recently bought and sold shares of CDXC. Merriman Wealth Management LLC bought a new stake in ChromaDex during the second quarter valued at about $32,000. Renaissance Technologies LLC raised its position in ChromaDex by 8.4% during the second quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after purchasing an additional 32,400 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of ChromaDex in the second quarter worth approximately $88,000. WINTON GROUP Ltd purchased a new stake in shares of ChromaDex in the second quarter worth approximately $597,000. Finally, Rhumbline Advisers bought a new position in ChromaDex in the second quarter worth approximately $124,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Insider Activity at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total transaction of $82,110.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.64% of the stock is owned by company insiders.

ChromaDex Price Performance

Shares of CDXC stock opened at $3.55 on Monday. ChromaDex Co. has a 1 year low of $1.25 and a 1 year high of $4.65. The business has a fifty day moving average of $3.36 and a 200 day moving average of $3.25. The firm has a market capitalization of $268.16 million, a price-to-earnings ratio of -71.00 and a beta of 1.86.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of ChromaDex in a research report on Friday, August 9th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.